The Phase 3 PEOPLE study evaluated the long-term effects of epicutaneous immunotherapy (EPIT) using the VIASKIN Peanut Patch, ...

Until now, he says research has been focused on those with severe peanut allergies, and the treatment has simply been for patients to avoid peanuts. "We've kind of ignored the fact that not ...

"These results validate 'hypoallergens' as a potential therapeutic against peanut allergy, which we hope to use as vaccines in sensitive individuals." A hypoallergen treatment would expose a ...

Palforzia® Oral Immunotherapy for the Treatment of Peanut Allergy Now Available in the U.S. for Pediatric Ages 1 Through 3 Years Stallergenes Greer, a global leader in allergy therapeutics ...

It's spring and if you feel like your seasonal allergies are worse every year, it’s not just in your head (or your sinuses).

SAN DIEGO — Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months ...

is now available for the treatment of pediatric patients aged 1 to 3 years with peanut allergy. Palforzia is indicated for the mitigation of allergic reactions, including anaphylaxis, that may ...

Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

Allergen Powder-dnfp] is now available for the treatment of pediatric patients aged 1 to 3 years with peanut allergy.

with a confirmed diagnosis of peanut allergy. Palforzia ® is the first and only U.S Food and Drug Administration (FDA) approved oral immunotherapy treatment (OIT) for the mitigation of allergic ...